Novavax Struggles Continue: Q4 2023 Earnings Disappoint
TL;DR
Novavax, a COVID-19 vaccine maker, anticipates flat or lower revenue for 2024 as it struggles to compete with larger rivals Pfizer and Moderna in the U.S. market. The company reported a larger-than-expected fourth-quarter loss and expects 2024 sales to be less than $25 million. Novavax aims to improve its market share by targeting retail pharmacy chains and offering more convenient prefilled syringes. Despite financial challenges and doubts about its ability to remain in business, the company plans to drive down costs and focus on commercial execution.
Topics:businessbusiness-healthcare#business-healthcare#covid-19-vaccine#financial-difficulties#market-share#novavax#revenue-forecast
- Novavax says still faces strong headwinds, 2024 sales flat to lower Yahoo Finance
- Novavax (NVAX) earnings report Q4 2023 CNBC
- Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year’ Barron's
- After steep cost cuts, Novavax's fourth-quarter performance falls short of expectations FiercePharma
- Novavax stock falls as Q4 results disappoint (NASDAQ:NVAX) Seeking Alpha
Want the full story? Read the original reporting
Read on Yahoo Finance